Why Are I-Mab Shares Trading Higher On Tuesday?

by Vandana Singh, Benzinga Editor
September 28, 2021 9:29 AM | 1 min read |
  • The Center for Drug Evaluation of China National Medical Products Administration has signed off I-Mab's IMAB IND application to initiate a Phase 2 trial for enoblituzumab in solid tumors.
  • The trial will evaluate enoblituzumab combined with Merck & Co Inc's MRK Keytruda (pembrolizumab) in patients with selected solid tumors in China. 
  • I-Mab has in-licensed the rights to exclusively develop and commercialize enoblituzumab in Greater China from MacroGenics Inc MGNX.
  • Enoblituzumab is an investigational Fc-optimized monoclonal antibody that targets B7-H3. 
  • Many different tumor types widely express B7-H3.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: IMAB stock is up 7.10% at $74.99 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsPhase 2 TrialSolid Tumorwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!